OncoMatch/Clinical Trials/NCT05892393
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
Is NCT05892393 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies Zirconium Zr 89-DFO-YS5 for multiple myeloma.
Treatment: Zirconium Zr 89-DFO-YS5 — This phase I trial tests the safety of \[89Zr\]DFO-YS5 positron emission tomography (PET) imaging and how well it works to detect CD46 positive cancer cells in patients with multiple myeloma. \[89Zr\]DFO-YS5 is an imaging agent called a radiopharmaceutical tracer. A radiopharmaceutical tracer uses a small amount of radioactive material that is injected into a vein to help image different areas of the body. \[89Zr\]DFO-YS5 targets a specialized protein called CD46, which is in certain multiple myeloma cancer cells, and \[89Zr\]DFO-YS5 PET scans may improve detection of multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Biomarker criteria
Required: CD46 expression (testing required; no eligibility threshold specified)
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
Required: FDG positive (uptake greater than liver on FDG PET)
At least one positive myelomatous lesion found on 18F-FDG PET/CT or PET/MRI. A positive lesion is defined as uptake greater than liver on FDG PET, based on the Italian myeloma criteria for PET use (IMPeTUs) criteria
Lab requirements
Kidney function
Creatinine clearance ≥ 30 mL/min, calculated using the Cockcroft-Gault equation or serum creatinine ≤ 1.5x the institutional upper limit of normal
Liver function
Total bilirubin ≤ 1.5 X institutional upper limit of normal (ULN); AST ≤ 3 X ULN; ALT ≤ 3 X ULN
Total bilirubin ≤ 1.5 X institutional upper limit of normal (ULN); AST ≤ 3 X ULN; ALT ≤ 3 X ULN; Creatinine clearance ≥ 30 mL/min, calculated using the Cockcroft-Gault equation or serum creatinine ≤ 1.5x the institutional upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05892393 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require CD46?
Yes, CD46 expression is a required biomarker for enrollment.
Does this trial require FDG?
Yes, FDG positive is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages